MediaCo Flaton Promoting Fisher to CRO
MediaCo Holding Inc. (NASDAQ: MDIA) shares began Monday slightly downward, on the news that the company announced the promotion of Brian Fisher to Chief Revenue Officer (CRO), effective immediately. In this role, Fisher will lead revenue-generating functions across the portfolio, including national and local sales for linear, audio, events, and digital.“Brian has been at the center of our growth story,” said Albert Rodriguez, CEO of MediaCo. “In recent quarters, we’ve achieved record revenue, strengthened key partnerships, and entered new markets. We expect continued digital revenue momentum in the upcoming quarter, building on record results from Q2. Brian’s leadership positions us well as we pursue our next phase of expansion.”Fisher most recently served as Senior Vice President of Video Sales, where he spearheaded innovation and revenue growth across digital, linear, and advanced TV platforms. He reportedly helped power a 345% surge in digital revenue during the first half of 2025, with digital now accounting for 33% of total advertising income. Prior to joining MediaCo, he held senior leadership roles at Disney (NYSE:DIS), Tribune, and McCann-Erickson, where he was known for developing and scaling cutting-edge advertising solutions. A graduate of the University of Arizona, Fisher is widely recognized for his expertise in multicultural marketing and his ability to guide teams through the rapidly changing media landscape.MDIA shares gave back three cents, or 2%, to $1.28.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


